Longeveron Inc. (LGVN) - 10-Q Summary
Business Context and Reporting Period
Company: Longeveron Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Longeveron is a clinical-stage biotechnology company developing laromestrocel (Lomecel-B), an allogeneic cellular therapy for Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy, and Aging-related Frailty. The company operates as a single segment focused on regenerative medicine.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenues | $287 | $685 | $697 |
| Cost of Revenues | $105 | $239 | $276 |
| Gross Profit | $182 | $446 | $421 |
| Operating Expenses | $6,353 | $11,392 | $10,999 |
| Net Loss | $(6,073) | $(10,809) | $(10,039) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.38) | $(0.67) |
| Cash and Cash Equivalents (Balance Sheet) | $10,077 (as of June 30, 2026) | ||
| Accumulated Deficit | $(143,120) (as of June 30, 2026) |
Liquidity & Debt: The company reported working capital of approximately $7.0 million. A new long-term liability of $778,000 was recorded related to the sale of an interest in future Priority Review Voucher (PRV) proceeds. There is no traditional debt, but the company has significant operating lease obligations.
Material Changes vs. Prior Period
- Revenue: Total revenue for the six months ended June 30, 2026, decreased slightly by $12,000 (2%) compared to the prior year period. This was driven by a decrease in contract manufacturing revenue (down $108,000) offset by an increase in clinical trial revenue from The Bahamas Registry Trial (up $108,000).
- Expenses: Operating expenses increased by $393,000 (4%) year-over-year for the six-month period. General and Administrative (G&A) expenses rose by $349,000 due to higher legal and accounting costs, while Research and Development (R&D) expenses remained relatively flat, increasing only $44,000.
- Financing Activity: The company completed the initial closing of a Private Placement in March 2026, raising approximately $15.9 million in gross proceeds. This included the issuance of Class A common stock, Series A preferred stock, and the sale of a 50% interest in future PRV proceeds.
- Stock Structure: Significant equity activity occurred, including the conversion of Series A preferred stock and Class B common stock to Class A, and the exercise of warrants.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Cash on hand ($10.1 million) is projected to fund operations only into the fourth quarter of 2026. Additional financing is required to meet minimum expenditure commitments for the next 12 months.
- Clinical Pipeline:
- HLHS (ELPIS II): The Phase 2b trial is fully enrolled. Top-line results are anticipated in September 2026. The FDA previously indicated the primary endpoint (RVEF) may be insufficient for efficacy, but agreed to review a composite endpoint plan submitted in June 2026.
- Alzheimer's Disease: Following a Type B meeting with the FDA, the company is seeking partnerships for a proposed seamless Phase 2/3 trial.
- Pediatric DCM: An IND application became effective in July 2025, with plans for a Phase 2 trial in 2027 subject to financing.
- Capital Raising: The company has an At-The-Market (ATM) facility with $9.3 million remaining available, though usage is restricted until the stock price trades above $0.80 per share (restriction lifts September 7, 2026). A second closing of the Private Placement (up to $15.0 million) is contingent on clinical milestones and stock price thresholds.
- Listing Status: The company is in a compliance period with Nasdaq to regain the $1.00 minimum bid price requirement by September 21, 2026. Failure to comply could result in delisting.
- Recent Developments: In August 2026, the company was selected as a Finalist in the XPRIZE Healthspan competition, receiving a $1.0 million Milestone 2 Award.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and the Q4 2026 funding horizon.
- ELPIS II Trial Design: Confirm the FDA's acceptance of the new composite primary endpoint plan submitted in June 2026, as the original endpoint was deemed insufficient.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by the September 21, 2026 deadline to avoid delisting.
- Private Placement Tranche 2: Assess the likelihood of achieving the clinical and stock price milestones required to trigger the second closing of the $15.0 million financing.
- Revenue Concentration: Note that contract manufacturing revenue has ceased, leaving The Bahamas Registry Trial as the primary revenue source, which is not a scalable commercial model.